Navigation

Bone metastases (hormone refractory prostate cancer) - denosumab [ID405]

Bone metastases (hormone refractory prostate cancer) - denosumab [ID405]

Status: Suspended
Expected date of issue: TBC
Referral date: November 2011
Process: STA
Notes:

Scoped within Batch 20.

Topic area:
  • Cancer
  • Urogenital
 

NICE project team

Executive Lead: TBC
Technical Lead: Richard Diaz
Communications manager: Alice Law
Project manager:

Lori Farrar

Top


 

Provisional schedule

Closing date for invited submissions / evidence submission: TBC
1st appraisal committee meeting: TBC
Top


 

Consultees and commentators

To be confirmed

Top


 

Project history

Date Update
28 November 2013

The Institute has now been informed by the manufacturer that it will no longer be pursuing a licensing application for denosumab in this indication, therefore, NICE has decided to suspend this appraisal on its current work programme.

As this topic has been referred to the Institute we will continue to monitor any development and will update interested parties if the situation changes.

17 April 2013 The manufacturer of Denosumab has informed NICE that they will not provide a submission for this appraisal. NICE has therefore suspended this appraisal.
Top


 

Key documents

This page was last updated: 04 March 2014

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.